Target intelligence / Profile preview

Zinc finger GRF-type containing 1 (ZGRF1)

Target
ZGRF1
Molecular classification
Enzyme: specifically DNA helicase (5'-3' directionality), Zinc finger protein (GRF-type)
01

Overview

Zinc finger GRF-type containing 1 (ZGRF1) is a nuclear DNA repair enzyme that contains a GRF-type zinc finger domain and a transmembrane region. It functions as a 5'-3' DNA helicase, crucial for resolving replication-blocking DNA lesions via homologous recombination. ZGRF1 physically interacts with the recombinase RAD51, stimulating strand exchange and promoting DNA repair. It catalyzes D-loop dissociation and Holliday junction branch migration, thereby ensuring genome stability. Loss of ZGRF1 impairs the repair of double-strand breaks, leads to chromosome aberrations, and hypersensitizes cells to agents inducing replication stress. Genetic variation within ZGRF1 has been implicated, albeit poorly understood, in metabolic phenotypes such as central fat deposition. The protein exhibits relatively low basal expression with cell cycle-regulated upregulation, notably peaking in S phase. Although not a direct target of drugs, ZGRF1 is vital for the cellular response to genotoxic chemotherapies by maintaining DNA integrity and preventing genome instability[1][2][3][4].

Other names
ZGRF1C4orf215'-3' DNA helicase ZGRF1GRF-type zinc finger domain-containing protein 1FLJ11331protein ZGRF1
02

Mechanism of action

Drugs causing DNA crosslinks or replication stress (e.g., mitomycin C, camptothecin) engage ZGRF1-mediated repair pathways, but ZGRF1 is not a direct pharmacological target[4].

03

Biological functions

Homologous recombinationDNA repair: promotes genome stability and repair of replication-blocking DNA lesionsD-loop dissociation and Holliday junction resolutionCell cycle regulation: promotes initiation of G2/M checkpoint in response to DNA damageMay have roles in metabolic processes and adiposity
04

Disease associations

Genome instability syndromes: DNA damage sensitivity, risk of chromosome aberrationsCancer: Loss can lead to chromosome instability, potentially cancer predispositionChildhood Apraxia of Speech, Scleral Staphyloma: reported disease associations, but mechanisms are unclearPotential involvement in adiposity traits
05

Safety considerations

Potential for genome instability if ZGRF1 function is inhibited or genetically lostNo known therapies targeting ZGRF1, so safety concerns specific to therapeutic modulation are unknown.

Beyond the preview

Go deeper on Zinc finger GRF-type containing 1 (ZGRF1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zinc finger GRF-type containing 1 (ZGRF1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call